SCHEMBL4073365

SCHEMBL4073365

Cc1[nH]c(=O)c2cc(Cl)ccc2c1C1CCCN1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 3/20 0.47
CDC7 O00311 1/20 0.47
CIT O14578 1/20 0.47
PIM1 P11309 1/20 0.47
CSNK2A2 P19784 1/20 0.47
GSK3B P49841 1/20 0.47
CSNK2B P67870 1/20 0.47
CSNK2A1 P68400 1/20 0.47
DYRK1A Q13627 1/20 0.47
CSNK2A3 Q8NEV1 1/20 0.47
TAOK3 Q9H2K8 1/20 0.47
PARP1 P09874 1/20 0.42
OPRM1 P35372 1/20 0.36
OPRD1 P41143 1/20 0.36
OPRK1 P41145 1/20 0.36
OPRL1 P41146 1/20 0.36
CSF1R P07333 1/20 0.36
TYMS P04818 1/20 0.36
LMNA P02545 2/20 0.35
TP53 P04637 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4079214 0.85 PARP1 (0.40) CYP1A2CDC7PARP1TYMSCHRM2
SCHEMBL4077456 0.82 CHRM5 (0.40) CYP1A2PARP1LMNACHRM2CHRM4
SCHEMBL4078132 0.79 PARP1 (0.44) CYP1A2PARP1OPRM1OPRD1OPRK1
SCHEMBL4069147 0.77 HTR3A (0.43) PARP1OPRM1OPRD1OPRK1OPRL1
SCHEMBL4079232 0.75 PARP1 (0.40) PARP1OPRM1OPRD1OPRK1OPRL1
SCHEMBL4073316 0.74 OPRM1 (0.48) PARP1OPRM1OPRD1OPRK1OPRL1
SCHEMBL4078373 0.72 OPRM1 (0.47) PARP1OPRM1OPRD1OPRK1OPRL1
SCHEMBL4072790 0.72 OPRM1 (0.54) PARP1OPRM1OPRD1OPRK1OPRL1
SCHEMBL10229093 0.71 PARP1 (0.58) CYP1A2PIM1PARP1TYMSLMNA
SCHEMBL4072256 0.71 OPRM1 (0.50) CDC7PARP1OPRM1OPRD1OPRK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7501412-B2 Isoquinoline compounds and medicinal use thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-03-10 US claimed
US-20060094743-A1 Isoquinoline compounds and medicinal use thereof MITSUBISHI PHARMA CORPORATION (JP) 2006-05-04 US claimed
EP-1566380-A1 ISOQUINOLINE COMPOUNDS AND MEDICINAL USE THEREOF Mitsubishi Pharma Corporation (JP) 2005-08-24 EP claimed
US-7501412-B2 Isoquinoline compounds and medicinal use thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-03-10 US disclosed
US-20060094743-A1 Isoquinoline compounds and medicinal use thereof MITSUBISHI PHARMA CORPORATION (JP) 2006-05-04 US disclosed
EP-1566380-A1 ISOQUINOLINE COMPOUNDS AND MEDICINAL USE THEREOF Mitsubishi Pharma Corporation (JP) 2005-08-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094743-A1 Isoquinoline compounds and medicinal use thereof PARP1, NQO1, PARP3 CYP1A2 1405/4885CDC7 3213/4885CIT 159/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.